Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT05809752
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
- NCT05809752 ↗
- Active, not recruiting
- H. Lee Moffitt Cancer Center and Research Institute
- Focused
We haven't built an HCP commentary report on NCT05809752 (dendritic cell vaccine in Leptomeningeal Disease) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
HCP commentary on NCT05809752 so far
What clinicians have said in podcasts, YouTube videos and X posts we have indexed. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) Administered Intrathecally (IT) Primed Against HER2/HER3 in Patients With Leptomeningeal Disease (LMD) From Triple-Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC)
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Leptomeningeal Disease; Triple Negative Breast Cancer; HER2-positive Breast Cancer
- Interventions
- Dendritic Cell Vaccine
- Arms
- Dendritic Cell (DC) Vaccine dose escalation · Experimental
- Enrollment
- 15
- Primary outcomes
- Maximum Tolerated Dose of Intrathecal Dendritic Cell Vaccine
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute with United States Department of Defense
- Start
- Aug 22, 2023
- Primary completion
- May 13, 2026
- Results posted
- No
- Registry record
- NCT05809752 · updated Sep 15, 2026